Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New obesity drug combo shows promise in early trial

NCT ID NCT06771115

Disease control Sponsor: Zomagen Biosciences Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called VTX3232, given alone or with the weight-loss drug semaglutide, in 176 adults with obesity. The main goal was to check safety and side effects over 12 weeks. Researchers also measured changes in inflammation levels. The trial is complete, but results are not yet public.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
VTX3232 (an experimental drug) and semaglutide (a weight-loss drug)
What this could lead to
If successful, this could point toward a new treatment option for obesity that reduces inflammation and helps with weight loss.
What could go wrong
This is an early phase 2a trial focused on safety, not weight loss. The results may not lead to an approved treatment, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

176 people

The number who actually took part.

Started

Jan 2025

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants are male or female ≥ 18 years up to ≤ 80 years of age. * Ability to comply with study requirements. * BMI ≥ 30.0 to ≤ 42.0 kg/m2 at screening. * Stable body weight (± 5%) for at least 3 months prior to screening. * hs-CRP ≥ 2 mg/L at screening. * Hypertension or hyperlipidemia which are known to be associated with increased risk of cardiovascular events, if present, must be controlled with stable dose/therapy. * History of at least one self-reported unsuccessful dietary effort to lose body weight. Exclusion Criteria: * Obesity induced by endocrinologic disorders, or diagnosed genetic or syndromic forms of obesity * Have any prior diagnosis of diabetes mellitus * Current participation (or within the last 3 months) in an organized weight reduction program. * History or presence of clinically significant gastric emptying abnormality (e.g., severe gastroparesis or gastric outlet obstruction) or chronically take drugs that directly affect GI motility, have undergone prior surgical treatment for obesity (e.g., gastric bypass \[bariatric\] surgery or restrictive bariatric surgery), or have an endoscopic and/or device-based therapy for obesity. * Clinically relevant medical condition(s) that put the participant at risk or will make implementation of the protocol or interpretation of the study difficult. * Use of any medication (e.g., GLP-1 agonists), nutritional supplement, or over the counter product for weight loss within the previous 6 months or during study participation, unless administered as a part of assigned study treatment in this study. * Receipt of the following medications: 1. Any immunosuppressive biologic or targeted therapy within 90 days prior to Day 1. 2. Use of anti-inflammatory medications within 30 days prior to Day 1 3. Colchicine within 30 days prior to Day 1. 4. Glucose-lowering agent(s) administered for conditions other than diabetes within 90 days before screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

Contacts and locations

Locations

  • 840001

    Largo, Florida, 33761, United States

  • 840002

    Austin, Texas, 78705, United States

  • 840003

    Lake Forest, California, 92630, United States

  • 840005

    Birmingham, Alabama, 35235, United States

  • 840006

    Dallas, Texas, 75230, United States

  • 840010

    Waco, Texas, 76710, United States

  • 840011

    Long Beach, California, 90815, United States

  • 840012

    Ocoee, Florida, 34761, United States

  • 840013

    San Antonio, Texas, 78229, United States

  • 840014

    Newton, Kansas, 67114, United States

  • 840015

    Marrero, Louisiana, 70072, United States

  • 840016

    Port Orange, Florida, 32127, United States

  • 840017

    Marrero, Louisiana, 70072, United States

  • 840018

    San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.